SEC Form 4
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
|
| OMB APPROVAL |
| OMB Number: |
3235-0287 |
| Estimated average burden |
| hours per response: |
0.5 |
|
|
|
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b). |
|
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. |
1. Name and Address of Reporting Person*
| C/O MIRA PHARMACEUTICALS, INC. |
| 1200 BRICKELL AVE. SUITE 1950 #1183 |
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
MIRA PHARMACEUTICALS, INC.
[ MIRA ]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
Director |
X |
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
|
|
|
3. Date of Earliest Transaction
(Month/Day/Year)
08/28/2024
|
4. If Amendment, Date of Original Filed
(Month/Day/Year)
|
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Form filed by One Reporting Person |
| X |
Form filed by More than One Reporting Person |
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
|---|
| 1. Title of Security (Instr.
3)
|
2. Transaction Date
(Month/Day/Year) |
2A. Deemed Execution Date, if any
(Month/Day/Year) |
3. Transaction Code (Instr.
8)
|
4. Securities Acquired (A) or Disposed Of (D) (Instr.
3, 4 and 5)
|
5.
Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr.
4)
|
7. Nature of Indirect Beneficial Ownership (Instr.
4)
|
| Code |
V |
Amount |
(A) or (D) |
Price |
| Common Stock |
08/28/2024 |
|
S |
|
200,000 |
D |
$1.96
|
2,540,270 |
I |
By Trust
|
| Common Stock |
|
|
|
|
|
|
|
10,000 |
D
|
|
| Common Stock |
|
|
|
|
|
|
|
660,000 |
I |
By Trust
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
|
|---|
| 1. Title of Derivative Security (Instr.
3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Transaction Date
(Month/Day/Year) |
3A. Deemed Execution Date, if any
(Month/Day/Year) |
4. Transaction Code (Instr.
8)
|
5.
Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
3, 4 and 5)
|
6. Date Exercisable and Expiration Date
(Month/Day/Year) |
7. Title and Amount of Securities Underlying Derivative Security (Instr.
3 and 4)
|
8. Price of Derivative Security (Instr.
5)
|
9.
Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
4)
|
10. Ownership Form: Direct (D) or Indirect (I) (Instr.
4)
|
11. Nature of Indirect Beneficial Ownership (Instr.
4)
|
| Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
1. Name and Address of Reporting Person*
| C/O MIRA PHARMACEUTICALS, INC. |
| 1200 BRICKELL AVE. SUITE 1950 #1183 |
(Street)
Relationship of Reporting Person(s) to Issuer
|
Director |
X |
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
|
|
|
1. Name and Address of Reporting Person*
| C/O MIRA PHARMACEUTICALS, INC. |
| 1200 BRICKELL AVE. SUITE 1950 #1183 |
(Street)
Relationship of Reporting Person(s) to Issuer
|
Director |
X |
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
|
|
|
| Explanation of Responses: |
|
|
|
/s/ Brian McNulty |
08/30/2024 |
|
** Signature of Reporting Person |
Date |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
| * If the form is filed by more than one reporting person,
see
Instruction
4
(b)(v). |
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure. |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |
Exhibit 24
POWER
OF ATTORNEY
The
undersigned as a Section 16 reporting person of MIRA Pharmaceuticals, Inc. (the “Company”), hereby constitutes and appoints
Michelle Yanez, signing singly, the undersigned’s true and lawful attorney in fact to:
(1) execute,
deliver and file for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of the Company,
Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder (the
“Exchange Act”);
(2) do
and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such
Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities
and Exchange Commission and any stock exchange or similar authority;
(3) seek
or obtain, as the undersigned’s representative and on the undersigned’s behalf, information on transactions in the Company’s
securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes
any such person to release any such information to the undersigned and approves and ratifies any such release of information; and
(4) take
any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit
to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact
on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as
such attorney-in-fact may approve in such attorney-in-fact’s discretion.
The
undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and
purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying
and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause
to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing
attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any
of the undersigned’s responsibilities to comply with Section 16 of the Exchange Act. The undersigned further acknowledges and agrees
that the attorney-in-fact and the Company are relying on written and oral information provided by the undersigned to complete such forms
and the undersigned is responsible for reviewing the completed forms prior to their filing. The attorney-in-fact and the Company are
not responsible for any errors or omissions in such filings. The attorney-in-fact and the Company are not responsible for determining
whether or not the transactions reported could be matched with any other transactions for the purpose of determining liability for short-
swing profits under Section 16(b).
This
Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect
to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned
in a signed writing delivered to the Company and the foregoing attorneys-in-fact.
[Signature
page follows.]
IN
WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this August 30, 2024
| |
 |
| |
Name: |
Brian McNulty |
[Signature
Page to Section 16 Power of Attorney]
Exhibit 24
POWER
OF ATTORNEY
The
undersigned as a Section 16 reporting person of MIRA Pharmaceuticals, Inc. (the “Company”), hereby constitutes and appoints
Michelle Yanez, signing singly, the undersigned’s true and lawful attorney in fact to:
(1) execute,
deliver and file for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of the Company,
Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder (the
“Exchange Act”);
(2) do
and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such
Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities
and Exchange Commission and any stock exchange or similar authority;
(3) seek
or obtain, as the undersigned’s representative and on the undersigned’s behalf, information on transactions in the Company’s
securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes
any such person to release any such information to the undersigned and approves and ratifies any such release of information; and
(4) take
any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit
to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact
on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as
such attorney-in-fact may approve in such attorney-in-fact’s discretion.
The
undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and
purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying
and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause
to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing
attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any
of the undersigned’s responsibilities to comply with Section 16 of the Exchange Act. The undersigned further acknowledges and agrees
that the attorney-in-fact and the Company are relying on written and oral information provided by the undersigned to complete such forms
and the undersigned is responsible for reviewing the completed forms prior to their filing. The attorney-in-fact and the Company are
not responsible for any errors or omissions in such filings. The attorney-in-fact and the Company are not responsible for determining
whether or not the transactions reported could be matched with any other transactions for the purpose of determining liability for short-
swing profits under Section 16(b).
This
Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect
to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned
in a signed writing delivered to the Company and the foregoing attorneys-in-fact.
[Signature
page follows.]
IN
WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this August 30, 2024
| |
|
| |
Name: |
Brian McNulty |
[Signature
Page to Section 16 Power of Attorney]
MIRA Pharmaceuticals (NASDAQ:MIRA)
過去 株価チャート
から 10 2024 まで 11 2024
MIRA Pharmaceuticals (NASDAQ:MIRA)
過去 株価チャート
から 11 2023 まで 11 2024
